Arrowstreet Capital
EVH icon

Arrowstreet Capital’s Evolent Health EVH Stock Holding History

Arrowstreet Capital’s Portfolio EVH Stock Details EVH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-194,863
Closed -$6.32M – 1295
2023
Q1 		$6.32M Buy
194,863
+93,501
+92% +$2.96M 0.01% 639
2022
Q4 		$2.85M Sell
101,362
-79,440
-44% -$2.28M ﹤0.01% 786
2022
Q3 		$6.5M Buy
180,802
+155,919
+627% +$5.49M 0.01% 601
2022
Q2 		$764K Buy
+24,883
New +$725K ﹤0.01% 988
2021
Q3 		– Sell
-341,055
Closed -$7.2M – 1667
2021
Q2 		$7.2M Sell
341,055
-452,732
-57% -$9.07M 0.01% 949
2021
Q1 		$16M Sell
793,787
-205,779
-21% -$3.91M 0.02% 677
2020
Q4 		$16M Buy
999,566
+72,875
+8% +$963K 0.02% 680
2020
Q3 		$11.5M Buy
926,691
+71,590
+8% +$842K 0.02% 776
2020
Q2 		$6.09M Buy
+855,101
New +$5.73M 0.01% 975
2019
Q2 		– Sell
-36,871
Closed -$464K – 1477
2019
Q1 		$464K Buy
+36,871
New +$584K ﹤0.01% 1499

Other funds holding EVH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Arrowstreet Capital's EVH Position: Q2 2023 in Review

Arrowstreet Capital sold out of Evolent Health (EVH) in Q2 2023, closing a stake of 194,863 shares — an estimated $6.32M sold.

Arrowstreet Capital first reported a position in EVH in Q1 2019 and held it in 10 quarters. The position peaked at $16M in Q1 2021. 217 funds tracked by Wall St. Rank hold EVH as of Q2 2023.

  • Arrowstreet Capital reported no remaining Evolent Health position as of Q2 2023 after selling out during the quarter.
  • Arrowstreet Capital sold 194,863 Evolent Health shares in Q2 2023, an estimated $6.32M.
  • Arrowstreet Capital first reported a position in Evolent Health in Q1 2019 and held it in 10 quarters.
  • Arrowstreet Capital's Evolent Health position peaked at $16M in Q1 2021.
  • 217 funds tracked by Wall St. Rank held Evolent Health as of Q2 2023.

Based on Arrowstreet Capital's 13F filing for Q2 2023, filed 14 Aug 2023.